Copyright
©2008 The WJG Press and Baishideng.
World J Gastroenterol. May 14, 2008; 14(18): 2851-2857
Published online May 14, 2008. doi: 10.3748/wjg.14.2851
Published online May 14, 2008. doi: 10.3748/wjg.14.2851
Table 1 Basal and demographic data
| Data | Group A Mesalamine + NAC (n = 19) | Group B Mesalamine + placebo (n = 18) | Total (n = 37) |
| Age (mean ± SD) | 51.4 ± 14 | 42.2 ± 13 | 46.9 ± 14 |
| White race, n (%) | 11 (57.8) | 13 (72.2) | 24 (64.8) |
| Smoker, n (%) | 2 (10.5) | 3 (16.7) | 5 (13.5) |
| Male, n (%) | 8 (42.1) | 5 (27.8) | 13 (35.1) |
| Basal modified Truelove-Witts severity index (mean ± SD) | 5.95 ± 2.22 | 4.61 ± 2.09 | 5.30 ± 2.20 |
- Citation: Guijarro LG, Mate J, Gisbert JP, Perez-Calle JL, Marín-Jimenez I, Arriaza E, Olleros T, Delgado M, Castillejo MS, Prieto-Merino D, Lara VG, Peña AS. N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: Randomized, placebo-controlled pilot study. World J Gastroenterol 2008; 14(18): 2851-2857
- URL: https://www.wjgnet.com/1007-9327/full/v14/i18/2851.htm
- DOI: https://dx.doi.org/10.3748/wjg.14.2851